These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2903712)

  • 21. What are the differences between the H2-receptor antagonists?
    Schunack W
    Aliment Pharmacol Ther; 1987; 1 Suppl 1():493S-503S. PubMed ID: 2908767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ranitidine v. cimetidine in peptic ulcer.
    Drug Ther Bull; 1982 Jul; 20(15):57-9. PubMed ID: 6128213
    [No Abstract]   [Full Text] [Related]  

  • 23. The treatment of "cimetidine resistant" peptic ulcers by ranitidine hydrochloride: a new histamine H2-receptor antagonist.
    Mohammed R; Mitchell KG; Mackay C
    Curr Med Res Opin; 1981; 7(8):523-5. PubMed ID: 6118237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A comparative evaluation of the efficacy of sucralfate and H2-histamine blockaders in treating peptic ulcer].
    Ivashkin VT; Tkachenko EI; Grinevich VB; Sultanov VK; Inozemtsev SA
    Ter Arkh; 1989; 61(8):59-62. PubMed ID: 2573963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
    Ohsawa T; Hirata W; Higichi S
    Int J Clin Pharmacol Res; 2002; 22(2):29-35. PubMed ID: 12503773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New drugs for peptic ulcer.
    Br Med J; 1980 Jul; 281(6233):95-6. PubMed ID: 6107146
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of acid inhibition on Campylobacter pylori.
    Blanco M; Pajares JM; Jimenez ML; Lopez-Brea M
    Scand J Gastroenterol Suppl; 1988; 142():107-9. PubMed ID: 2901784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical review of histamine2 receptor antagonists.
    Lipsy RJ; Fennerty B; Fagan TC
    Arch Intern Med; 1990 Apr; 150(4):745-51. PubMed ID: 1970232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection.
    Freston JW
    Am J Gastroenterol; 1987 Dec; 82(12):1242-9. PubMed ID: 2891294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Famotidine: a further development in the modern treatment of peptic ulcer disease. Proceedings of a satellite symposium of the XIIth International Congress of Gastroenterology. Lisbon, September 19, 1984.
    Digestion; 1985; 32 Suppl 1():1-72. PubMed ID: 2866131
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.
    Bardhan KD; Naesdal J; Bianchi Porro G; Petrillo M; Lazzaroni M; Hinchliffe RF; Thompson M; Morris P; Daly MJ; Carroll NJ
    Gut; 1991 Apr; 32(4):435-8. PubMed ID: 1673953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Is strong inhibition of gastric acid in the treatment of peptic ulcer sensible?].
    de Bruijne JW; Lamers CB
    Ned Tijdschr Geneeskd; 1989 Apr; 133(13):657-62. PubMed ID: 2566125
    [No Abstract]   [Full Text] [Related]  

  • 33. [Therapy and prevention of duodenal and gastric ulcer with histamine-H2-receptor antagonists].
    Hentschel E
    Wien Med Wochenschr; 1983; 133(4-5):104-7. PubMed ID: 6134397
    [No Abstract]   [Full Text] [Related]  

  • 34. [I.v. famotidine versus i.v. ranitidine: intragastric pH behavior in surgical intensive care patients].
    Friedl W; Krier C; Dammann HG; Müller P; Simon B
    Z Gastroenterol; 1985 Nov; 23(11):603-7. PubMed ID: 2868579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New H2-blockers: does more choice help?
    Drug Ther Bull; 1988 Aug; 26(17):65-6. PubMed ID: 3138097
    [No Abstract]   [Full Text] [Related]  

  • 36. Candida overgrowth in gastric juice of peptic ulcer subjects on short- and long-term treatment with H2-receptor antagonists.
    Boero M; Pera A; Andriulli A; Ponti V; Canepa G; Palmas F; Duglio A; Molinaro GC; Toselli M; Riccardino N
    Digestion; 1983; 28(3):158-63. PubMed ID: 6141973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Famotidine versus ranitidine in the acute treatment of duodenal ulcer. A multicenter comparative study in Germany].
    Simon B; Dammann HG; Jakob G; Miederer SE; Müller P; Ottenjann R; Paul F; Scholten T; Schütz E; Seifert E
    Z Gastroenterol; 1985 Feb; 23(2):47-51. PubMed ID: 2865859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic approach in patients with concomitant disease/drug--drug interactions (roxatidine acetate).
    Collins JD
    Scand J Gastroenterol Suppl; 1988; 146():89-99. PubMed ID: 2906472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histology of gastric biopsies from peptic ulcer patients before and after short-term treatment with omeprazole or H2-receptor antagonists.
    Helander HF; Simonsson M; Sundler F; Rutgersson K; Helander KG; Eriksson S
    Virchows Arch A Pathol Anat Histopathol; 1990; 417(4):305-9. PubMed ID: 1978433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Modified H2 receptor blockers in ulcus therapy].
    Domschke S; Domschke W
    Dtsch Med Wochenschr; 1982 Dec; 107(48):1827-30. PubMed ID: 6128214
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.